Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Paclitaxel 4Cyclophosphamide 4exemestane 3Taxes 3Tamoxifen 3Letrozole 3Doxorubicin 3Anastrozole 3Trastuzumab 2Leuprolide 2Immunotherapy 2Goserelin 2Carboplatin 2trastuzumab biosimilar HLX02 1ribociclib 1pegfilgrastim 1elacestrant 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Vitamins 1Standard of Care 1Radiosurgery 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1PF-05280014 1Ontruzant 1Omeprazole 1Ogivri 1Neoadjuvant Therapy 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Indomethacin × 1 year × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡